Review Article
Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases
Table 6
Selected drugs for targeted melanoma therapy.
| | Target(s) | Drug | Phase(s) trial | Protocol_IDs* |
| | BRAF | PLX4032 | II | NCT00949702 | | III | NCT01006980 |
| | ARAF | RAF265 | In Phase 1 for malignant melanoma | NCT00304525 | | BRAF | | CRAF | | VEGFR-2 |
| RAF
PDGFR
VEGFR-2 | Sorafenib | Modest activity against melanoma | — |
| | BRAF | GSK2118436 | III | NCT01227889 | | | II | NCT01153763 |
| | MEK | AZD6244 | II | NCT00866177 |
| | MEK | GSK1120212 | III | NCT01245062 |
| | MEK | AZD8330 | In phase I for (advanced malignancies) | NCT00454090 |
| | Hsp90 | AT13387 | In phase I for (solid tumors) | NCT00878423 |
| | c-KIT | Dasatinib | II | NCT00436605 |
| | c-KIT | Gleevec | III, | NCT00470470 | | II | NCT00667953 |
| | c-KIT | Tasigna | III | NCT01028222 |
| | c-KIT | Sutent | II | NCT00631618 |
| | GNAQ | GSK1120212 | III | NCT01245062 | | GNA11 |
| | HDAC | Panobinostat | I, | NCT00925132 | | III | NCT01065467 |
| | HDAC1 | Valproic acid | I | NCT00495872 |
| | PI3K | | | | | MTOR1 | SF1126 | In phase I for (advanced malignancies) | NCT00658671 | | MTOR2 | | | |
| | AKT | MK2206 | In phase I for (solid tumors) | NCT00848718 |
| | MTOR | OSI-027 | In phase I for (advanced solid tumors) | NCT00698243 |
| | CDK4 | Flavopiridol/alvocidib/HMR 1275 | II | NCT00005971 |
| | CDK4 | P276-00 | II | NCT00835419 |
| | CDK4 | UCN-01 | II | NCT00072189 |
|
|
*Randomized clinical trials selected from http://mmdm.cancercommons.org/ml/index.php/A_Melanoma_Molecular_Disease_Model.
|
